Literature DB >> 19249973

Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.

Coenraad F M Hendriksen1.   

Abstract

Models to measure potency in vaccine research and development and preclinical testing are frequently based on an immunization-challenge procedure in laboratory animals. These models have proven to be very instrumental in scientifically underpinning the correlation of protection of selected vaccine antigens and their efficacy. In vivo models in vaccine research and development are, for the time being, irreplaceable, although significant progress has been made in using in vitro prescreening tests to evaluate particular immunological parameters. For a long time, in vivo potency tests have been similarly relevant for routine vaccine lot-release testing. The design of a potency test, defined in most pharmacopeias, relied on a direct or indirect-challenge procedure in laboratory animals. For various reasons, there now is an increased interest in the development of alternatives to the current in vivo potency tests. Animal models have their limitations, with respect to their relevance, reliability, costs and moral acceptability. All alternative approaches have in common that they ultimately result in a refinement, reduction or replacement in the use of animals. The new models range from modifications of the existing in vivo test procedure (e.g., use of humane end points or serology instead of challenge) to in vitro antigen-quantification tests. A new paradigm in quality control of vaccines is the consistency approach. This approach is state-of-the-art in quality control of the new-generation vaccines and it is now finding its way into the quality control of traditional vaccines. The consistency approach implies the use of a set of parameters to constitute a product profile, which is monitored throughout production, and which guarantees that each lot released is similar to a manufacturer-specific vaccine of proven clinical efficacy and safety. Consistency relies heavily on the implementation of quality systems, such as good manufacturing practice and quality assurance, and on the use of in vitro analytical tools, such as immunochemical and physicochemical tests.

Mesh:

Substances:

Year:  2009        PMID: 19249973     DOI: 10.1586/14760584.8.3.313

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  16 in total

Review 1.  Vaccines to combat the neglected tropical diseases.

Authors:  Jeffrey M Bethony; Rhea N Cole; Xiaoti Guo; Shaden Kamhawi; Marshall W Lightowlers; Alex Loukas; William Petri; Steven Reed; Jesus G Valenzuela; Peter J Hotez
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Core body temperature as adjunct to endpoint determination in murine median lethal dose testing of rattlesnake venom.

Authors:  Charles C Cates; James G McCabe; Gregory W Lawson; Marcelo A Couto
Journal:  Comp Med       Date:  2014-12       Impact factor: 0.982

3.  Modular microfluidic system as a model of cystic fibrosis airways.

Authors:  M Skolimowski; M Weiss Nielsen; F Abeille; P Skafte-Pedersen; D Sabourin; A Fercher; D Papkovsky; S Molin; R Taboryski; C Sternberg; M Dufva; O Geschke; J Emnéus
Journal:  Biomicrofluidics       Date:  2012-08-02       Impact factor: 2.800

4.  Markers for predicting death as an outcome for mice used in infectious disease research.

Authors:  Rita A Trammell; Linda A Toth
Journal:  Comp Med       Date:  2011-12       Impact factor: 0.982

5.  IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.

Authors:  Josef Singer; Erika Jensen-Jarolim
Journal:  J Carcinog Mutagen       Date:  2014-05-31

6.  Substitute of Animals in Drug Research: An Approach Towards Fulfillment of 4R's.

Authors:  T Arora; A K Mehta; V Joshi; K D Mehta; N Rathor; P K Mediratta; K K Sharma
Journal:  Indian J Pharm Sci       Date:  2011-01       Impact factor: 0.975

Review 7.  Public perception of laboratory animal testing: Historical, philosophical, and ethical view.

Authors:  Francesca Petetta; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2020-12-16       Impact factor: 4.093

Review 8.  Alternatives to animal testing: A review.

Authors:  Sonali K Doke; Shashikant C Dhawale
Journal:  Saudi Pharm J       Date:  2013-11-18       Impact factor: 4.330

9.  Proteomic analysis of chicken bone marrow-derived dendritic cells in response to an inactivated IBV + NDV poultry vaccine.

Authors:  Robin H G A van den Biggelaar; Larissa van der Maas; Hugo D Meiring; Jeroen L A Pennings; Willem van Eden; Victor P M G Rutten; Christine A Jansen
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

10.  Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the Schistosoma mansoni Tetraspanin 2 vaccine.

Authors:  Guangzhao Li; Lara Hoeweler; Brian Keegan; Jin Peng; Larissa Scholte; Peter Hotez; Maria Elena Bottazzi; David Diemert; Jeffrey Bethony
Journal:  Vaccine X       Date:  2021-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.